Its reporting season in New Zealand in May and these 5 ASX companies are about to report annual results
Its always reporting season in New Zealand in May as well as November, because many companies there follow an April…
Immutep (ASX:IMM): Set to commercialise its cancer treatment Efti by 2027
Developing a cancer drug is a long journey, but Immutep (ASX:IMM) is more towards the end than the start. A…
The Latest OPEC Production Increase is 411,000 Barrels! Here’s What It Means for Global Oil Prices
The latest OPEC production increase could hit oil prices hard. OPEC (Organisation of the Petroleum Exporting Countries) has decided to…
Labor’s 2025 Win: 5 Stocks Set to Soar Under the New Government
As Australia heads into a new political era with Labor’s win in 2025, investors are paying close attention to the…
This Phase 3 ASX biotech is on the brink of unlocking market opportunities worth a cumulative US$9.1bn
Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) is a Phase 3 ASX biotech that is close to unlocking its market opportunity. It is…
Which will be the next ASX gold stocks to be acquired? Here are 3 possible candidates
Investors are wondering which will be the next ASX gold stocks to be acquired. There has been a flurry of…
XPON Technologies (ASX:XPN): Here’s why its shares skyrocketed >300% in just a few hours
XPON Technologies (ASX:XPN) achieved something on Monday May 5 that few companies achieve – rising more than 200% in a…
Warren Buffett is retiring, will hand the top job at Berkshire to Greg Abel by the end of 2025. Here’s what you need to know
After many decades at the helm of Berkshire Hathaway, Warren Buffett is retiring. After founding his empire in 1965, he…
Here are 4 of the worst red flags for stocks that you need to watch out for
Investors should always be on the look out for red flags for stocks. We’re talking about subtle signs that may…
Capricorn Metals (ASX:CMM): Its sequel gold mine will be even better than the original
Capricorn Metals (ASX:CMM) is one of several gold miners on the ASX that has slid under the radar of many…
What Does China’s Slowdown Mean for Australian Investors? When Will the Impact Start to Show?
China, Australia’s largest trading partner, plays a crucial role in shaping the economic landscape for Australian investors. As one of…
US Recession Fears Are Rising: What Sectors and Stocks Will Stay Strong and Which Will Struggle?
As the possibility of a US recession looms over global financial markets, investors are grappling with the implications of this…
ESG (Economic, Social and Governance) investing in 2025: Here’s an investor’s ultimate guide
ESG has become one of the most popular acronyms in the investing world, and a quickly growing trend. Few investors…
Microsoft and Meta Are Holding Their Ground in 2025—Is Now the Right Time to Invest?
As we move into 2025, two tech giants, Microsoft and Meta, continue to dominate the global digital landscape. Both companies…
Kidney disease-focused biotech Dimerix announced a US licensing deal for DMX-200! And this could be the best deal of all!
Dimerix has been targeting a US licensing deal for DMX-200 and the dreams are now a reality as of this…